1. 主頁
  2. Au, Chi Ho Ivan

區志豪

區志豪
博士後研究員

衞生經濟、政策和管理學

  • BSc (HKU), PhD (HKU)
phone 2831 5307
email auchiho@hku.hk
orcid ORCID: 區志豪
个人简介
Dr Ivan Au Chi-ho obtained his PhD from the School of Public Health at the University of Hong Kong. His research interests include valuation and mapping of health-related quality of life measures, evaluation of real-world effectiveness of antiviral treatments and safety of vaccines for infectious diseases, application of target trial emulation for causal inference in pharmacoepidemiology, and development and validation of artificial intellengce applications in medicine.
发表的部分文章
  1. Ivan C.H. Au, Nan Luo, Zhihao Yang, Fredrick D. Purba, Oliver Rivero-Arias, Prudence W.H. Cheung, Jason P.Y. Cheung, Eliza L.Y. Wong, Carlos K.H. Wong. Comparisons of Preferences Toward EQ-5D-Y-3L Health States Between Adult Own and Child Perspectives. Value in Health. 2025. DOI: 10.1016/j.jval.2025.06.008
  2. Carlos K.H. Wong, Kristy T.K. Lau, Ivan C.H. Au, Sophelia H.S. Chan, Eric H.Y. Lau, Benjamin J. Cowling, Gabriel M. Leung. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation. Nature Communications. 2024. DOI: 10.1038/s41467-024-49235-8 (co-first author)
  3. Carlos K.H. Wong*, Kristy T.K. Lau*, Matthew S.H. Chung*, Ivan C.H. Au*, Ka Wang Cheung, Eric H.Y. Lau, Yasmin Daoud, Benjamin J. Cowling, Gabriel M. Leung. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation. Nature Medicine. 2023. DOI: 10.1038/s41591-023-02674-0 (co-first author)
  4. Carlos K.H. Wong*, Kristy T.K. Lau*, Ivan C.H. Au*, Eric H.Y. Lau, Benjamin J. Cowling. Comparison of Bivalent and Monovalent mRNA Vaccine Boosters. Clinical Infectious Diseases. 2023. DOI: 10.1093/cid/ciad519 (co-first author)
  5. Carlos K.H. Wong*, Lung Yi Mak*, Ivan C.H. Au*, Wing Yiu Cheng, Ching Hei So, Kristy T.K. Lau, Eric H.Y. Lau, Benjamin J. Cowling, Gabriel M. Leung, Man Fung Yuen. Risk of acute liver injury following the nirmatrelvir /ritonavir use. Liver International. 2023. DOI: 10.1111/liv.15673 (co-first author)
  6. Carlos K.H. Wong*, Ivan C.H. Au*, Wing Yiu Cheng*, Kenneth K.C. Man, Kristy T.K. Lau, Lung Yi Mak, Sing Leung Lui, Matthew S.H. Chung, Xi Xiong, Eric H.Y. Lau, Benjamin J. Cowling. Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: A self-controlled case series study. Alimentary Pharmacology & Therapeutics. 2022. DOI: 10.1111/apt.16894 (co-first author)
  7. David T.W. Lui*, Ivan C.H. Au*, Eric H.M. Tang, Ching Lung Cheung, Chi Ho Lee, Yu Cho Woo, Tingting Wu, Kathryn C.B. Tan, Carlos K.H. Wong. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. EClinicalMedicine. 2022. DOI: 10.1016/j.eclinm.2022.101510 (co-first author)
  8. Carlos K.H. Wong, Kristy T.K. Lau, Ivan C.H. Au, Eric H.Y. Lau, Leo L.M. Poon, Ivan F.N. Hung, Benjamin J. Cowling, Gabriel M. Leung. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. The Lancet Infectious Diseases. 2023. DOI: 10.1016/S1473-3099(22)00873-8 (co-author)
  9. Carlos K.H. Wong, Ivan C.H. Au, Kristy T.K. Lau, Eric H.Y. Lau, Benjamin J. Cowling, Gabriel M. Leung. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. The Lancet. 2022. DOI: 10.1016/S0140-6736(22)01586-0 (co-author)
  10. Carlos K.H. Wong, Ivan C.H. Au, Kristy T.K. Lau, Eric H.Y. Lau, Benjamin J. Cowling, Gabriel M. Leung. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. The Lancet Infectious Diseases. 2022. DOI: 10.1016/s1473-3099(22)00507-2 (co-author)
返回